Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NC134
- Development stage
- Preclinical
- Lead developer
- NanoNeurosciences
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
NC134 is a preclinical nanocarrier-based peptide therapy being developed by NanoNeurosciences for the treatment of primary open-angle glaucoma (POAG). The therapy is designed as an intranasal formulation that targets neurotensin receptor type 1 (NTSR1) in trabecular meshwork (TM) cells. By activating NTSR1, NC134 stimulates actin cytoskeleton dynamics and cellular energy-boosting mechanisms within TM cells, which are critical for regulating aqueous humor drainage. This dual-action approach aims to restore TM cell function, reduce resistance to fluid outflow, and lower intraocular pressure (IOP) to prevent optic nerve damage and vision loss.
02
Targets
NTR1 (Nitroreductase-1)
Beyond the preview
Go deeper on NC134.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NC134.